Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02442960 · ClinicalTrials.gov registry record · Phase 1
Evaluating Safety and Efficacy of Herbal Treatment in Ulcerative Colitis
A Phase 1 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT02442960: Completed Phase 1 study, sponsored by Stanford University.
NCT02442960 is a Phase 1 study that has completed, run by Stanford University. The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02442960, a Phase 1 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This is a 12-week, open-label, dose-escalation Phase 1b study of a herbal treatment given orally to subjects with ulcerative colitis. Subjects will be sequentially enrolled to one of two cohorts in up to two clinical sites. Treatment will be given for 8 weeks and study duration will be 12 weeks.
Interventions
- DRUG Herbal treatment (SA100)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2014-12 |
| Est. Completion | 2017-07-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02442960
The ClinicalTrials.gov registry entry for NCT02442960 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Herbal treatment (SA100) is the first listed.
NCT02442960 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02442960 about?
NCT02442960 is a clinical study titled "Evaluating Safety and Efficacy of Herbal Treatment in Ulcerative Colitis". This is a 12-week, open-label, dose-escalation Phase 1b study of a herbal treatment given orally to subjects with ulcerative colitis. Subjects will be sequentially enrolled to one of two cohorts in up to two clinical sites. Treatment will be given for 8 weeks and study duration will be 12 weeks.
What is the current status of trial NCT02442960?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2014-12. Estimated completion is 2017-07-26.
What interventions are being tested in trial NCT02442960?
The interventions under investigation include: Herbal treatment (SA100) (DRUG).
Who is sponsoring clinical trial NCT02442960?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.